Effect of blood sample type on the measurement of advanced oxidation protein products as a biomarker of inflammation and oxidative stress in hemodialysis patients

References

• Abou-Seif MA, Youssef AA.(2004).Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta 346:161–70.
   PubMed Web of Science ®Google Scholar
• Antolini F, Valente F, Ricciardi D, Baroni M, Fagugli RM.(2005).Principal component analysis of some oxidative stress parameters and their relationships in hemodialytic and transplanted patients. Clin Chim Acta 358:87–94.
   PubMed Web of Science ®Google Scholar
• Baskol G, Demir H, Baskol M, Kilic E, Ates F, Karakukcu C,Ustdal M.(2006).Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid arthritis. Cell Biochem Funct 24:307–11.
   PubMed Web of Science ®Google Scholar
• Baskol M, Baskol G, Kocer D, Ozbakir O, Yucesoy M.(2008).Advanced oxidation protein products: a novel marker of oxidative stress in ulcerative colitis. J Clin Gastroenterol 42:687–91.
   PubMed Web of Science ®Google Scholar
• Bradley PP, Christensen RD, Rothstein G.(1982).Cellular and extracellular myeloperoxidase in pyogenic inflammation. Blood 60:618–22.
   PubMed Web of Science ®Google Scholar
• Capeillere-Blandin C, Gausson V, Descamps-Latscha B, Witko-Sarsat V.(2004).Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochim Biophys Acta 1689:91–102.
   PubMed Web of Science ®Google Scholar
• Capeillere-Blandin C, Gausson V, Nguyen AT, Descamps-Latscha B, Drueke T, Witko-Sarsat V.(2006).Respective role of uraemic toxins and myeloperoxidase in the uraemic state. Nephrol Dial Transplant 21:1555–63.
   PubMed Web of Science ®Google Scholar
• Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, London GM, Jungers P.(2005).Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 45:39–47.
   PubMed Web of Science ®Google Scholar
• Ding Feng ZHU, Qiu-yu GU, Yong LIN, Shan-yan. (2006).Analysis of major component of advanced oxidation protein products. Chin J Nephrol 22:33–36.
   Google Scholar
• Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM.(2002).Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106:2212–7.
   PubMed Web of Science ®Google Scholar
• Gaffney PJ, Wong MY.(1992).Collaborative study of a proposed international standard for plasma fibrinogen measurement. Thromb Haemost 68:428–32.
   PubMedGoogle Scholar
• Himmelfarb J.(2004).Linking oxidative stress and inflammation in kidney disease: which is the chicken and which is the egg?. Semin Dial 17:449–54.
   PubMed Web of Science ®Google Scholar
• Himmelfarb J, McMonagle E.(2001).Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 60:358–63.
   PubMed Web of Science ®Google Scholar
• Irish A.(1998).Cardiovascular disease, fibrinogen and the acute phase response: associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 137:133–9.
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD.(2003).Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63:793–808.
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Brennan ML, Hazen SL.(2006).Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am J Kidney Dis 48:59–68.
   PubMed Web of Science ®Google Scholar
• Kalousova M, Skrha J, Zima T.(2002).Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 51:597–604.
   PubMed Web of Science ®Google Scholar
• Kaplan B, Cojocaru M, Unsworth E, Knecht A, Martin BM.(2003).Search for peptidic “middle molecules” in uremic sera: isolation and chemical identification of fibrinogen fragments. J Chromatogr B Analyt Technol Biomed Life Sci 796:141–53.
   PubMed Web of Science ®Google Scholar
• Kaysen GA, Dubin JA, Muller HG, Mitch WE, Rosales L, Levin NW.(2003).Impact of albumin synthesis rate and the acute phase response in the dual regulation of fibrinogen levels in hemodialysis patients. Kidney Int 63:315–22.
   PubMedGoogle Scholar
• Kocak H, Oner-Iyidogan Y, Gurdol F, Oner P, Suzme R, Esin D, Issever H.(2007).Advanced oxidation protein products in obese women: its relation to insulin resistance and resistin. Clin Exp Med 7:173–8.
   Google Scholar
• Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, Kronenberg F.(1997).Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 8:1889–98.
   PubMed Web of Science ®Google Scholar
• Kozek-Langenecker SA, Masaki T, Mohammad H, Green W, Mohammad SF, Cheung AK.(1999).Fibrinogen fragments and platelet dysfunction in uremia. Kidney Int 56:299–305.
   PubMed Web of Science ®Google Scholar
• Krasniak A, Drozdz M, Pasowicz M, Chmiel G, Michalek M, Szumilak D, Podolec P, Klimeczek P, Konieczynska M, Wicher-Muniak E, Tracz W, Khoa TN, Souberbielle JC, Drueke TB, Sulowicz W.(2007).Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol Dial Transplant 22:515–21.
   PubMed Web of Science ®Google Scholar
• Li HY, Hou FF, Zhang X, Chen PY, Liu SX, Feng JX, Liu ZQ, Shan YX, Wang GB, Zhou ZM, Tian JW, Xie D.(2007).Advanced oxidation protein products accelerate renal fibrosis in a remnant kidney model. J Am Soc Nephrol 18:528–38.
   PubMed Web of Science ®Google Scholar
• Liu SX, Hou FF, Guo ZJ, Nagai R, Zhang WR, Liu ZQ, Zhou ZM, Zhou M, Xie D, Wang GB, Zhang X.(2006).Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 26:1156–62.
   PubMed Web of Science ®Google Scholar
• Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, Wang M, Xu GB, Wang HY.(2006).Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17:2937–44.
   PubMed Web of Science ®Google Scholar
• Marquez LA, Dunford HB.(1995).Kinetics of oxidation of tyrosine and dityrosine by myeloperoxidase compounds I and II. Implications for lipoprotein peroxidation studies. J Biol Chem 270:30434–40.
   PubMed Web of Science ®Google Scholar
• Massy ZA, Ivanovski O, Nguyen-Khoa T, Angulo J, Szumilak D, Mothu N, Phan O, Daudon M, Lacour B, Drueke TB, Muntzel MS.(2005).Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol 16:109–16.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Hazen SL.(2005).Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 25:1102–11.
   PubMed Web of Science ®Google Scholar
• Nowak P, Zbikowska HM, Ponczek M, Kolodziejczyk J, Wachowicz B.(2007).Different vulnerability of fibrinogen subunits to oxidative/nitrative modifications induced by peroxynitrite: functional consequences. Thromb Res 121:163–74.
   PubMed Web of Science ®Google Scholar
• Pecoits-Filho R, Stenvinkel P, Marchlewska A, Heimburger O, Barany P, Hoff CM, Holmes CJ, Suliman M, Lindholm B, Schalling M, Nordfors L.(2003).A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl S172–6.
   Google Scholar
• Selmeci L, Szekely M, Soos P, Seres L, Klinga N, Geiger A, Acsady G.(2006).Human blood plasma advanced oxidation protein products (AOPP) correlates with fibrinogen levels. Free Radic Res 40:952–8.
   PubMed Web of Science ®Google Scholar
• Shacter E, Williams JA, Lim M, Levine RL.(1994).Differential susceptibility of plasma proteins to oxidative modification: examination by western blot immunoassay. Free Radic Biol Med 17:429–37.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimburger O, Cederholm T, Girndt M.(2005).IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia–the good, the bad, and the ugly. Kidney Int 67:1216–33.
   PubMed Web of Science ®Google Scholar
• Thekkedath UR, Chirananthavat T, Leypoldt JK, Cheung AK, Mohammad SF.(2006).Elevated fibrinogen fragment levels in uremic plasma inhibit platelet function and expression of glycoprotein IIb-IIIa. Am J Hematol 81:915–26.
   Google Scholar
• Thomas MC, Tikellis C, Burns WM, Bialkowski K, Cao Z, Coughlan MT, Jandeleit-Dahm K, Cooper ME, Forbes JM.(2005).Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 16:2976–84.
   PubMed Web of Science ®Google Scholar
• Valli A, Suliman ME, Meert N, Vanholder R, Lindholm B, Stenvinkel P, Watanabe M, Barany P, Alvestrand A, Anderstam B.(2007).Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. Clin Chim Acta 379:87–94.
   PubMed Web of Science ®Google Scholar
• Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B.(1996).Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49:1304–13.
   PubMed Web of Science ®Google Scholar
• Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillere-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drueke T, Descamps-Latscha B.(1998).Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161:2524–32.
   PubMed Web of Science ®Google Scholar
• Yazici C, Kose K, Calis M, DemIr M, Kirnap M, Ates F.(2004).Increased advanced oxidation protein products in Behcet’s disease: a new activity marker?. Br J Dermatol 151:105–11.
   PubMed Web of Science ®Google Scholar